雷米布鲁丁尼布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.
Drugs
|January 20, 2026
概括
雷米布鲁丁尼布是一种新的口服布鲁顿氨酸激酶 (BTK) 抑制剂,已被批准用于成人慢性自发性疹 (CSU). 这标志着症状性CSU不对抗胰岛素药物反应的患者的显著进展.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
背景情况:
- 慢性自发性疹 (CSU) 是一种使人虚弱的疾病,通常不耐标准治疗.
- 布鲁顿的氨酸激酶 (BTK) 在免疫细胞激活中起着关键作用,与CSU的发病有关.
研究的目的:
- 总结雷米布鲁丁尼布在CSU的发展里程碑.
- 为了突出雷米布鲁丁尼布在症状性CSU的首次监管批准.
主要方法:
- 对雷米布鲁丁尼布的临床前和临床开发数据的审查.
- 对监管提交和批准时间表的分析.
主要成果:
- 雷米布鲁丁尼布是一种选择性BTK抑制剂,已经经历了广泛的开发.
- 首次批准于2025年9月30日在美国授予,用于症状性CSU的成年患者,尽管接受了H1-抗组胺药物治疗.
- 随后在中国获得批准,在欧盟和日本正在进行审查.
结论:
- 雷米布鲁丁尼布代表了CSU的新疗法选择.
- 批准意味着在管理CSU方面迈出了一大步,为未满足需求的患者提供了希望.
相关概念视频
FDA Approved Drugs: Changes to Approved Drugs
246
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
246
Obedience
35.2K
According to obedience research, we may harm others under the forceful pressures of an authority figure (Milgram, 1974). How about if the inappropriate orders were delivered with less force? The increasing interdependence between nurses and physicians compelled Hofling and his colleagues to explore nurses’ reactions to a potentially harmful medical request made by the perceived authority figure, the doctor (Hofling, Brotzman, Dalrymple, Graves, & Pierce, 1966). In this situation,...
35.2K
Ethics in Research
25.4K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
25.4K


